Janani Krishnamurthy Email & Phone Number

Thousand Oaks, CA

• Led a high-functioning team of scientists through pre-clinical, translational research and process development of EBV-specific mesothelin CAR-T cell therapy to treat solid tumor. Selected contributions include:
• Built and guided teams to develop off-the-shelf cell therapy, allogeneic ATA3271, from pre-clinical research to process development; this product was licensed for $600 million by Bayer.
• Devised and oversaw clinical product release assay development for patient derived ATA2271 cell therapy product in collaboration with Memorial Sloan Kettering Cancer Center.
• Developed assay techniques for deep characterization for Phase III clinical product, TAB cell, and accrued ancillary data for Biological License Application (BLA) filing with FDA.
• Managed BOD communication and advised on projects related to the development of a unique virus-specific cell therapy for the treatment of multiple sclerosis

Thousand Oaks, CA

Lead EBV+ve CAR-T cell pre-clinical initiatives for targeting solid tumor.

Cambridge, MA

• Managed teams working on R&D and process development for innovative immune therapy platform technology. Managed BOD, scientific advisory board (SAB) and investor communications as company moved from stealth biotech in.
• Designed and conducted in vitro and in vivo pre-clinical experiments for IND-filing to initiate Phase-1 clinical trial (Gavo-cel).
• Spearheaded the transformation of pre-clinical process (including QC release assays development) to clinically scalable platforms, SOP development.
• Identified and recruited contract research and manufacturing organizations (CROs and CDMO), and managed successful technology transfer for manufacturing from lab to CDMO site.
• Advanced company R&D portfolio utilizing microRNA technology for unique IP filing.

Greater Boston Area

Cambridge, Massachusetts

• Assessed unique single chain fragments in the context of CAR molecules and developing unique TCR-specific T cell platform for solid tumor. Selected Contributions:
• Developed platform technology to test immune safety features of cell therapy products in vitro.
• Optimized immunotherapeutic assays to assess novel mechanisms of gene knockdown in TCR-specific T cell therapy in vitro and in vivo.

Houston, Texas Area

Human Application of Engineered Chimeric Antigen Receptor (CAR) T-cellsPatent dateIssued Mar 14, 2014 Patent issuer and numberus PCT/US2014/038005Targeted adoptive T cell therapy by developing genetically engineered chimeric antigen receptor (CAR)+ T cells. My work involves targeting the envelope of an ancient human retrovirus (HERV-K) using antigen.

Mountain View, California

Developed and standardized protocols and SOPs for immunoflourescence (IF) staining and time lapse microscopy on suspension cells. Consultant for cytotoxicity assay development.

San Antonio, Texas Area

Part time Teaching assiatant: Lab instructor for freshman biology lab (2yrs) Part time Research assistant:Analyzed the effects and immunological events during doxycyclin treatment for neurocysticercosis in murine brain. realtime PCR, histopathological analysis and and confocal microscopy was performed for this purpose.

Executive Mba

Doctor Of Philosophy (Ph.D.)

Master'S Degree

Bachelor Of Pharmacy (B.Pharm.)